Lepper, E.R.

irinotecan patient clearance cyp 3a cancer midazolam erythromycin breath test pharmacokinetic erythromycin treatment minute midazolam clearance breath cancer institute -38 sn -38g verweij j midazolam clearance test variant metabolism irinotecan clearance cyp 3a phenotype sample sn -38 parameter 20- minute point irinotecan pharmacokinetics 40 minutes curve concentration ugt 1a fi rst analysis 14 co 2 allele signi probe cer curve infusion study institute verweij activity cytochrome blood value sparreboom bruijn p cyp 3a activity range body surface area colorectal cancer metabolite correlation percentage point extent oncol plasma nooter k jonge mj loos wj phenotyping genotype variability pharmacol signi ficantly phenotype mathijssen table ugt 1a genotype journal fi rst treatment ficant enzyme ethyl effect midazolam concentration colorectal 600 mg